Media headlines about Vertex Pharmaceuticals (NASDAQ:VRTX) have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vertex Pharmaceuticals earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave news stories about the pharmaceutical company an impact score of 45.141807537452 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the headlines that may have impacted Accern Sentiment’s scoring:
- Vertex Pharmaceuticals Incorporated, (NASDAQ: VRTX) – Lookout for Volatility – Stock Watch (stocksnewstimes.com)
- Investors need to focus on Analysts Rating: Vertex Pharmaceuticals Incorporated (VRTX) – Wall Street Morning (wallstreetmorning.com)
- Vertex Pharmaceuticals Incorporated (VRTX) EVP Sells $2,406,250.00 in Stock (americanbankingnews.com)
- Vertex to Present at the Cowen Healthcare Conference on March 13 (finance.yahoo.com)
- Analysts Expect Vertex Pharmaceuticals Incorporated (VRTX) Will Post Quarterly Sales of $608.99 Million (americanbankingnews.com)
Shares of Vertex Pharmaceuticals (NASDAQ VRTX) traded down $0.58 on Wednesday, reaching $174.38. The company’s stock had a trading volume of 1,036,592 shares, compared to its average volume of 2,030,000. The firm has a market cap of $44,270.00, a P/E ratio of 167.67, a PEG ratio of 2.52 and a beta of 1.56. Vertex Pharmaceuticals has a 52-week low of $88.90 and a 52-week high of $178.25. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.28 and a quick ratio of 3.14.
Vertex Pharmaceuticals declared that its Board of Directors has approved a stock buyback program on Wednesday, January 31st that authorizes the company to buyback $500.00 million in outstanding shares. This buyback authorization authorizes the pharmaceutical company to repurchase shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company’s management believes its shares are undervalued.
VRTX has been the topic of several recent analyst reports. HC Wainwright reiterated a “hold” rating and issued a $103.00 price target on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 13th. Deutsche Bank initiated coverage on Vertex Pharmaceuticals in a research note on Tuesday, December 12th. They issued a “buy” rating and a $175.00 price target on the stock. Zacks Investment Research upgraded Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $176.00 price target on the stock in a research note on Monday, January 8th. Oppenheimer lifted their price target on Vertex Pharmaceuticals from $175.00 to $190.00 and gave the company an “outperform” rating in a research note on Thursday, January 4th. Finally, BidaskClub upgraded Vertex Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 24th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and twenty-five have issued a buy rating to the company’s stock. Vertex Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $183.96.
In other Vertex Pharmaceuticals news, CMO Jeffrey Chodakewitz sold 5,122 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $150.82, for a total transaction of $772,500.04. Following the transaction, the chief marketing officer now directly owns 73,485 shares of the company’s stock, valued at approximately $11,083,007.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Thomas Graney sold 777 shares of Vertex Pharmaceuticals stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $149.95, for a total value of $116,511.15. The disclosure for this sale can be found here. Insiders have sold a total of 356,966 shares of company stock worth $57,081,624 over the last ninety days. Company insiders own 1.80% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://baseballnewssource.com/2018/03/07/vertex-pharmaceuticals-vrtx-getting-somewhat-favorable-media-coverage-report-shows/1974414.html.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.